

EXPRESS MAIL CERTIFICATE
"EXPRESS MAIL" MAILING LABEL NUMBER EL808219584
DATE OF DEPOSIT 16 JANUARY 2002



Attorney Docket No. P31005C6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Browne, *et al.* 16 January 2002
Serial No.: Not assigned Group Art Unit No.: Not assigned
Filed: Herewith Examiner: Not assigned
For: NOVEL COMPOUNDS

Assistant Commissioner for Patents
Washington, D.C. 20231

BEST AVAILABLE COPY

FILING OF AN INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not, however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited reference is enclosed, except for those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,

Kirk Baumeister
Attorney for Applicants
Registration No. 33,833

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5096
Facsimile (610) 270-5073

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31005C6	SERIAL NO. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Browne, <i>et al.</i>	
		FILING DATE Herewith	GROUP Unknown

31000 U.S. PTO
 10/050227
 01/16/02

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
AA	5,349,053	9/20/94	Landolfi	530	351	
AB	5,723,118	3/3/98	W. Sebald	424	85.2	
AC	6,130,318	10/10/00	Wild <i>et al.</i>	530	351	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
AD	0 367 166	5/9/90	EP	A61K	37/02		
AE	0 396 387	11/7/90	EP	A61K	47/48		
AF	WO 88/07089	9/22/88	PCT	C12N	15/20		
AG	WO 91/01004	1/24/91	PCT	G01N	33/53		
AH	WO 94/04680	3/3/94	PCT	C12N	15/24		
AI	CA 2,045,869	12/29/91	Canada	C12P	021/02		

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

AJ	Zurawski, et al., "Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction", <u>The EMBO Journal</u> , <u>12 No. 7</u> , pp. 2663-2670 (1993)
AK	Angal, et al., "A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody", <u>Molecular Immunology</u> , <u>30, No. 1</u> , pp. 105-108 (1993)
AL	Kreitman, et al., "Site-Specific Conjugation to Interleukin 4 Containing Mutated Cysteine Residues Produces Interleukin 4-Toxin Conjugates with Improved Binding and Activity", <u>Biochemistry</u> , <u>33</u> , pp. 11637-11644 (1994)
AM	Kruse, et al., "Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement", <u>The EMBO Journal</u> , <u>11, No. 9</u> , pp. 3237-3244 (1992)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY

Sheet 2 of 2

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31005C6	SERIAL NO. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Browne, et al.	
		FILING DATE Herewith	GROUP Unknown

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation	
					Yes	No

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

AN	Kruse, et al., "Site-directed mutagenesis reveals the importance of disulfide bridges and aromatic residues for structure and proliferative activity of human Interleukin-4", <u>FEBS</u> , <u>286</u> , No. 1,2, pp. 58-60 (1991)
AO	Kruse, et al., "Two distinct functional sites of human interleukin 4 are identified by variants impaired in either receptor binding or receptor activation", <u>The EMBO Journal</u> , <u>12</u> , No. 13, pp. 5121-5129 (1993)
AP	Burgess, et al., "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue", <u>The Journal of Cell Biology</u> , <u>111</u> , pp. 2129-2138 (1990)
AQ	Lazar, et al., "Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities", <u>Molecular and Cellular Biology</u> , <u>8</u> , No. 3, pp. 1247-1252 (1988)
AR	Tao, et al., "Studies of Aglycosylated Chimeric Mouse-Human IgG", <u>The Journal of Immunology</u> , <u>143</u> , pp. 2595-2601
AS	Gillies, et al., "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities", <u>Hum. Antibod. Hybridomas</u> , <u>1</u> , No. 1, pp. 47-54 (1990)
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.